Skip to content

A randomized controlled study on the protective effect of RIPC in patients undergoing cardiac surgery.

A randomized controlled study on the protective effect of RIPC in patients undergoing cardiac surgery.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033689
Enrollment
Unknown
Registered
2020-06-09
Start date
2020-07-01
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac surgery

Interventions

experimental group:the tourniquet preattached to the right upper arm was inflated, and the inflation pressure was kept at 200mmHg or 50mmHg higher than the patient's basic blood pressure for 5 minutes
control group:The tourniquet was fastened to the right upper limb in the same RIPC group, but it was not inflated or deflated.

Sponsors

Zhongshan Hospital Affiliated to Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aortic valve, mitral valve, tricuspid valve, ascending aortic disease, coronary atherosclerosis, admission. Patients undergoing elective valve repair, replacement, artificial vascular replacement or coronary artery bypass grafting. 2. Aged 18-80 years. 3. No restriction on gender. 4. ASA grade II~III. 5. NYHAII~III level. 6. The patient or his family member has signed the informed consent form for the clinical trial.

Exclusion criteria

Exclusion criteria: 1. Those who are disabled in the selected test. 2. Less than 5 years of education. 3. The preoperative left ventricular ejection fraction (LVEF) was less than 40%. 4. Myocardial infarction occurred in nearly one month. 5. Malignant tumor, hematological disease, severe liver and kidney dysfunction, recent severe infection, etc. 6. History of nervous system, immune system and mental illness. 7. Recent operation history of heart, brain, lung, liver, kidney and other important organs.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative delirium;Incidence of postoperative acute renal injury;

Secondary

MeasureTime frame
Postoperative ventilator assisted ventilation time;Postoperative ICU hospitalization time;Total postoperative hospital stay;

Countries

China

Contacts

Public ContactGuo Kefang

Zhongshan Hospital Affiliated to Fudan University

guo.kefang@zs-hospital.sh.cn+86 13817706936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026